AIM
ARRY

Alambic Investment Management’s Array Biopharma Inc ARRY Stock Holding History

Alambic Investment Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-26,200
Closed -$440K – 423
2018
Q2 		$440K Buy
+26,200
New +$417K 0.12% 227
2017
Q4 		– Sell
-26,923
Closed -$331K – 562
2017
Q3 		$331K Sell
26,923
-15,619
-37% -$145K 0.04% 391
2017
Q2 		$356K Sell
42,542
-152,488
-78% -$1.25M 0.04% 432
2017
Q1 		$1.74M Buy
195,030
+21,800
+13% +$232K 0.21% 168
2016
Q4 		$1.52M Sell
173,230
-17,900
-9% -$132K 0.27% 127
2016
Q3 		$1.29M Buy
191,130
+45,342
+31% +$175K 0.3% 106
2016
Q2 		$519K Buy
145,788
+91,188
+167% +$297K 0.13% 271
2016
Q1 		$161K Buy
54,600
+18,700
+52% +$56K 0.05% 416
2015
Q4 		$151K Buy
+35,900
New +$164K 0.09% 308

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Alambic Investment Management's ARRY Position: Q3 2018 in Review

Alambic Investment Management sold out of Array Biopharma Inc (ARRY) in Q3 2018, closing a stake of 26,200 shares — an estimated $440K sold.

Alambic Investment Management first reported a position in ARRY in Q4 2015 and held it in 9 quarters. The position peaked at $1.74M in Q1 2017. 208 funds tracked by Wall St. Rank hold ARRY as of Q3 2018.

  • Alambic Investment Management reported no remaining Array Biopharma Inc position as of Q3 2018 after selling out during the quarter.
  • Alambic Investment Management sold 26,200 Array Biopharma Inc shares in Q3 2018, an estimated $440K.
  • Alambic Investment Management first reported a position in Array Biopharma Inc in Q4 2015 and held it in 9 quarters.
  • Alambic Investment Management's Array Biopharma Inc position peaked at $1.74M in Q1 2017.
  • 208 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2018.

Based on Alambic Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.